| Title |
Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
|
|---|---|
| Published in |
Advances in Therapy, July 2013
|
| DOI | 10.1007/s12325-013-0043-2 |
| Pubmed ID | |
| Authors |
Leticia De Mattos-Arruda, Javier Cortes |
| Abstract |
Targeting the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors has proven to be effective as a therapeutic strategy for HER type 2 (HER2)-positive breast cancer. Since resistance to trastuzumab occurs relatively frequently, particularly in the metastatic setting, novel anti-HER2 targeted therapies with complementary and/or synergistic mechanisms of action have been under development. Pertuzumab, a HER2-targeted monoclonal antibody that prevents HER2 dimerisation, is the first of a class of promising targeted agents for the treatment of HER2-positive breast cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 4% |
| Japan | 1 | 2% |
| Unknown | 43 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 15% |
| Student > Bachelor | 7 | 15% |
| Student > Master | 6 | 13% |
| Student > Ph. D. Student | 5 | 11% |
| Student > Postgraduate | 3 | 7% |
| Other | 8 | 17% |
| Unknown | 10 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 33% |
| Biochemistry, Genetics and Molecular Biology | 7 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Agricultural and Biological Sciences | 2 | 4% |
| Nursing and Health Professions | 1 | 2% |
| Other | 4 | 9% |
| Unknown | 13 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2013.
All research outputs
#17,691,177
of 22,714,025 outputs
Outputs from Advances in Therapy
#1,488
of 2,332 outputs
Outputs of similar age
#142,270
of 197,947 outputs
Outputs of similar age from Advances in Therapy
#8
of 16 outputs
Altmetric has tracked 22,714,025 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,332 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,947 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.